when was semaglutide patented Last week's expiry of the patent for semaglutide—the active ingredient in Novo Nordisk's blockbuster drugs that are used to treat both diabetes and obesity—unleashed a flurry of launches of low-cost generic versions Growing concerns over semaglutide weight

It is worth noting that research comparing GLP-1RAs with six anti-diabetes drugs revealed that there is no significant difference in lowering the risk of HCC between GLP-1RAs and metformin or DDP-4i (Wang et al., 2024)

Although Mounjaro is newer and perhaps more costly, its efficacy could prove to be worth the cost in some individuals

Chapter 4 | - If It Could Happen to Me, What Will Happen to You

As retatrutide is not yet approved by the MHRA, its full safety profile continues to be established through ongoing trials

Expert Eye Care for Ozempic Users in London If youre taking a GLP-1 medication and something about your eyes is worrying you, you dont have to navigate it alone

He is also the Founder and Chairman of the Food Fix Campaign , dedicated to transforming our food and agriculture systems through policy